Resources - Scientific Posters Multiplexed Assay for IL-6 Secretion and Cell Viability using an Epithelial Ovarian Cancer Cell LineDownload
Related Products: Cytation 3
January 21, 2014
Authors: Andreas Rieger, Brad Larson and Peter Banks, BioTek Instruments, Inc., Winooski, Vermont, USA; Nicolas Pierre, Suzanne Graham and Francois Degorce, Cisbio Bioassays, Codolet, France; Stephanie Georgiou, Enzo Life Sciences, Farmingdale, New York, USA
According to the Centers of Disease Control and Prevention (CDC), each year about 20,000 women in the United States are diagnosed with ovarian cancer. 90% of these cancers are classified as "epithelial" and are believed to arise from the surface (epithelium) of the ovary and are termed Epithelial Ovarian Cancer (EOC). While prognosis is good with early diagnosis, in disease stages I/II, symptoms are non-specific and difficult to trace. The majority of ovarian cancers are diagnosed at late stage III/ IV, where symptoms become more evident. Unfortunately at this point, prognosis is poor. A common manifestation of EOC at this late stage of its progression is a build-up of fluid in the abdominal cavity (ascites). It has been shown that high levels of IL-6 are present in patients with ascites.